Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16628497 | 0.81 | MGLL (0.76) | MGLLIDO1AOC3ABCC1CA12 | |
| SCHEMBL28815421 | 0.80 | MGLL (0.73) | MGLLIDO1AOC3ABCC1CA12 | |
| SCHEMBL27992535 | 0.80 | MGLL (0.73) | MGLLIDO1AOC3ABCC1CA12 | |
| SCHEMBL7226798 | 0.78 | AOC3 (0.57) | TAAR1MGLLAOC3ABCC1SIGMAR1 | |
| SCHEMBL11608786 | 0.77 | NPC1 (0.48) | MGLLABCC1NPY5RMLYCD | |
| SCHEMBL2922045 | 0.76 | MEN1 (0.56) | KDM4E | |
| SCHEMBL11528815 | 0.75 | ABCC1 (0.58) | TAAR1MGLLAOC3ABCC1SIGMAR1 | |
| SCHEMBL1520363 | 0.73 | KMT2A (0.59) | TAAR1AOC3ABCC1NPY5RCA12 | |
| SCHEMBL11527982 | 0.72 | ABCC1 (0.56) | TAAR1IDO1AOC3ABCC1SIGMAR1 | |
| SCHEMBL20561075 | 0.72 | TAAR1 (0.57) | TAAR1AOC3ABCC1NPY5RCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105907-A1 | Novel IDO inhibitors and methods of use thereof | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-05-10 | — | — | US | claimed |
| US-20100166881-A1 | Novel IDO Inhibitors and Methods of Use Thereof | PRENDERGAST GEORGE C | 2010-07-01 | — | — | US | disclosed |
| US-7705022-B2 | N-[2-(Indol-3-yl)ethyl]-S-methyl-dithiocarbamate; N-[2-(benzo[b]thiophen-3-yl)ethyl]-S-methyl-dithiocarbamate; N-[2-(indol-3-yl)ethyl]-S[(naphth-2-yl)methyl]-dithiocarbamate; anticarcinogenic agents; free of brassinin | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-04-27 | — | — | US | disclosed |
| US-20070105907-A1 | Novel IDO inhibitors and methods of use thereof | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166881-A1 | Novel IDO Inhibitors and Methods of Use Thereof | IDO1, IDO2, INMT | TAAR1 1895/4885MGLL 940/4885IDO1 1/4885 |
| US-20070105907-A1 | Novel IDO inhibitors and methods of use thereof | IDO1, IDO2, INMT | TAAR1 1895/4885MGLL 940/4885IDO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.